How to Buy Keros Therapeutics Stock
Keros Therapeutics Inc
Keros Therapeutics, Inc. , a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options.
Keros Therapeutics stock last closed at $10.65, up 2.31% from the previous day, and has decreased 21.4% in one year. It has overperformed other stocks in the Biotechnology industry by 0.5 percentage points. Keros Therapeutics stock is currently +9.91% from its 52-week low of $9.69, and -52.77% from its 52-week high of $22.55.
At the moment, there are 19.79M KROS shares outstanding. The market cap of KROS is $210.78M. In the last 24 hours, 400,000 KROS shares were traded.
How to Buy Keros Therapeutics Stock
Wondering how to invest in Keros Therapeutics stock? Here's how.
- Figure out where to buy Keros Therapeutics stock: You need to choose a stock brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you choose where to buy Keros Therapeutics stock.
- Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit funds into your investment account: Pick your method of payment and add your information.
- Research Keros Therapeutics stock: The Keros Therapeutics ticker symbol is KROS. Is Keros Therapeutics stock a good investment? Should you buy shares of KROS? How do KROS's underlying business fundamentals look? Do top analysts think Keros Therapeutics is a good buy? Why has KROS's stock price moved recently? (Hint: Our stock market analysis website can help you figure out if KROS is a good stock to buy).
- Place your KROS purchase: Decide if you will purchase KROS shares at the current market price or use a limit order to buy KROS stock at a particular price.
- Monitor your investment in KROS: Create a watchlist to important notifications about your investment in Keros Therapeutics stock.
Step 1: Figure out where to buy Keros Therapeutics stock
You need an online brokerage account in order to access the NASDAQ market and buy KROS shares.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to world financial markets: From Tech to Energy, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro boasts a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've selected the right brokerage, you need to fill out some personal info so you are able to invest in KROS today.
How to Set Up a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to start your new trading account.
- Send your info by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you've opened your account on the stocks app, your next step is to transfer the money for your investment:
Check out the walkthrough below if you need help transferring money into your new brokerage account.
Step 4: Research Keros Therapeutics stock
Once you have figured out the best place to buy Keros Therapeutics stock, it's very important to research their stock before you buy, so you actually wrap your head around the risk as well as the upside.
Keros Therapeutics shares quick numbers
Keros Therapeutics Due Diligence Score
WallStreetZen was built to help average investors perform more accurate fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on KROS's stock page.
Is KROS stock undervalued?
Analysts use many financial metrics, analyses, models, and charts to gauge KROS's fair value.
Using relative valuations methods:
- KROS may be undervalued based on its P/B ratio of 0.74x, relative to Biotechnology industry P/B ratio of 4.95x
You can do additional valuation analysis on KROS's stock here.
Is KROS a healthy company?
Signs that KROS is financially healthy:
- KROS has a low debt to equity ratio of 0.09.
- There are more short-term assets than short-term liabilities on the KROS balance sheet.
- KROS has cash burn of 58254000. It has sufficient cash and short-term investments to cover this for at least one year.
- KROS has $282.95M in cash and short term investments. This is enough to cover its annual cash burn of $58.25M.
- There are more short-term assets than long-term liabilities on the KROS balance sheet.
Signs that KROS is not financially healthy:
- Total KROS debt is higher than 5 years ago, relative to shareholder equity.
- KROS profit margin has gone down from 2% to -256.6% in the past year.
Do Wall Street analysts think it's a good time to buy KROS stock
Out of 1 Equities analysts who give recommendations on KROS, the consensus analyst rating on Keros Therapeutics is a Strong Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they financial advice.
You can dive deeper into what analysts are forecasting on the Keros Therapeutics stock forecast page.
KROS Technical Indicators
KROS Performance Numbers
Last year, KROS revenue was $33.18M. During the last four year, KROS's revenue has grown by 13.35% per year. This was slower than the Biotechnology industry average of 32.37%.
Dig into KROS's earnings and revenue performance here.
Latest Insiders Trades at KROS
In the past year, insiders at KROS have sold more shares than they have bought.
Jean Jacques Bienaime, Director of KROS, was the latest KROS insider to buy. They bought $10,190.00 worth of KROS stock on Jun 15, 2026.
Get more info about who owns KROS shares here.
Can I rely on KROS as an income stream?
No, Keros Therapeutics doesn't provide an income stream by paying out dividends.
KROS Social Trading Data
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
Step 5: Place your KROS purchase
There are two main types of orders:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are generally fine. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a specific dollar amount limit, use a limit order.
Hit the Open Trade button and eToro will place the order.
If you need more help with investing in stocks on eToro, watch the how to video below:
Step 6: Monitor your investment in KROS
Now that you own some shares in KROS, you'll want to keep up with your stock purchase.
Start a watchlist to keep tabs on your KROS stock.
KROS Feed
How to Buy Stock in Keros Therapeutics
To summarize, here are the 6 steps you need to take to buy Keros Therapeutics stock right now:
- Figure out where to buy Keros Therapeutics stock
- Open a brokerage account
- Deposit funds into your investment account
- Research Keros Therapeutics stock
- Place your KROS purchase
- Monitor your investment in KROS
If you need a brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to get the latest scoop on your investment in Keros Therapeutics, add KROS to your watchlist below.
Trending Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.